| Dr Won Suk Choi, MD | |
|
830 Prairie Center Dr, Eden Prairie, MN 55344-7301 | |
| (952) 826-6500 | |
| (952) 826-6584 |
| Full Name | Dr Won Suk Choi |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 830 Prairie Center Dr, Eden Prairie, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114189289 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 54318 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Home Care And Hospice | Minneapolis, MN | Home health agency |
| Fairview Southdale Hospital | Edina, MN | Hospital |
| Fairview Ridges Hospital | Burnsville, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Clinics | 7113830142 | 658 |
News Archive
Pain management can be safely optimized with a plan that balances the risks and benefits of treatments, according to a commentary in Mayo Clinic Proceedings. Treating chronic pain is best achieved when pharmacologic strategies and nondrug therapies are used at the same time.
Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.
NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today financial results for the quarter ended March 31, 2010.
People with a waistline of one meter or more are at serious risk of insulin resistance - an early stage in the development of diabetes and heart disease, finds a study published online by the BMJ.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Pain management can be safely optimized with a plan that balances the risks and benefits of treatments, according to a commentary in Mayo Clinic Proceedings. Treating chronic pain is best achieved when pharmacologic strategies and nondrug therapies are used at the same time.
Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.
NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today financial results for the quarter ended March 31, 2010.
People with a waistline of one meter or more are at serious risk of insulin resistance - an early stage in the development of diabetes and heart disease, finds a study published online by the BMJ.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Pain management can be safely optimized with a plan that balances the risks and benefits of treatments, according to a commentary in Mayo Clinic Proceedings. Treating chronic pain is best achieved when pharmacologic strategies and nondrug therapies are used at the same time.
Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.
NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today financial results for the quarter ended March 31, 2010.
People with a waistline of one meter or more are at serious risk of insulin resistance - an early stage in the development of diabetes and heart disease, finds a study published online by the BMJ.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Won Suk Choi, MD 830 Prairie Center Dr, Eden Prairie, MN 55344-7301 Ph: (952) 826-6500 | Dr Won Suk Choi, MD 830 Prairie Center Dr, Eden Prairie, MN 55344-7301 Ph: (952) 826-6500 |
News Archive
Pain management can be safely optimized with a plan that balances the risks and benefits of treatments, according to a commentary in Mayo Clinic Proceedings. Treating chronic pain is best achieved when pharmacologic strategies and nondrug therapies are used at the same time.
Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.
NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today financial results for the quarter ended March 31, 2010.
People with a waistline of one meter or more are at serious risk of insulin resistance - an early stage in the development of diabetes and heart disease, finds a study published online by the BMJ.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
Dr. David Michael Hefner, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16490 W 78th St, Eden Prairie, MN 55346 Phone: 952-934-5332 | |
Aaron Timmerman, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8455 Flying Cloud Dr, Eden Prairie, MN 55344 Phone: 952-993-7400 | |
Dr. Sally A Kline, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8455 Flying Cloud Dr, Ste 200, Eden Prairie, MN 55344 Phone: 952-993-7400 | |
Benjamin W Chaska, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 18026 Bearpath Trl, Eden Prairie, MN 55347 Phone: 952-906-2962 | |
Kinsey Cornick, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8455 Flying Cloud Dr, Eden Prairie, MN 55344 Phone: 952-993-7400 | |
Dr. Christine M Hamilton, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16490 W 78th St, Eden Prairie, MN 55346 Phone: 304-225-2500 Fax: 304-985-6350 |